Topics:

Osteoporosis

Can the "Formulary Police" Be Stopped?

Demands for prior approvals (PAs) have begun to spread, virus-like, from top-dollar biologics to familiar standards such as methotrexate. A quick survey by an Alabama rheumatologist reveals the additional high cost to practices of merely dealing with all those PAs. And who's practicing rheumatology now -- you or those health-plan clerks? What can be done? He offers a solution ...

Osteoporosis

Antinuclear antibody testing and DEXA both appear on a new Canadian list of rheumatology tests to avoid and on a similar 2013 list from the American College of Rheumatology. There are interesting differences in the other 3 choices.

In this video, Steven R. Goldstein, MD, professor of obstetrics and gynecology at NYU, discusses new research he presented in October at the 25th annual North American Menopause Society meeting.

New data boosts confidence in drug therapies for osteoporosis, but more research in older adults is required.

A review article in the Medical Letter highlights appropriate use and limitations of bisphosphonates, denosumab, and other osteoporosis treatment, along with the associated costs.

Menopause will be unique for each woman, and a physician-patient partnership is a must if women want effective menopause management.

Osteoporosis isn't a disease of older women; it's a disease of all women, incubating in even our youngest patients.

Pages

Subscribe to Osteoporosis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.